Evidence map›Paper›PMID 31365783›Full record

ArticleChemMedChem2019

Synthesis and Preliminary Evaluation of [

Zhen Chen, Tuo Shao, Wei Gao, Hualong Fu, Thomas Lee Collier, Jian Rong, Xiaoyun Deng, Qingzhen Yu, Xiaofei Zhang, April T Davenport and 6 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Development ofPharmaceuticals (Basel, Switzerland) · 2025
    Article
  3. Review
  4. Article
  5. Review
  6. Exploring the focal role of LRRK2 kinase in Parkinson's disease.Environmental science and pollution research international · 2022
    Review
  7. The role of neuroimaging in Parkinson's disease.Journal of neurochemistry · 2021
    Review
  8. Radiosynthesis and evaluation of 4-(6-[RSC medicinal chemistry · 2020
    Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Zhen ChenDepartment of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA.
Tuo ShaoDepartment of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA.
Wei GaoShanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, 500 Dongchuan Road, Shanghai, 200241, China.
Hualong FuDepartment of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA.
Thomas Lee CollierDepartment of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA.
Jian RongDepartment of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA.
Xiaoyun DengDepartment of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA.
Qingzhen YuDepartment of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA.
Xiaofei ZhangDepartment of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA.
April T DavenportDepartment of Physiology and Pharmacology, Wake Forest School of Medicine, Winston Salem, NC, 27157, USA.
James B DaunaisDepartment of Physiology and Pharmacology, Wake Forest School of Medicine, Winston Salem, NC, 27157, USA.
Hsiao-Ying WeyAthinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA.
Yihan ShaoDepartment of Chemistry and Biochemistry, University of Oklahoma, Norman, OK, 73019, USA.
Lee JosephsonDepartment of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA.
Wen-Wei QiuShanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, 500 Dongchuan Road, Shanghai, 200241, China.
Steven LiangDepartment of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA.ORCID 0000-0003-1413-6315
Harvard University · USEast China Normal University · CNWake Forest University · USUniversity of Oklahoma · US

Funding

Monkey Alcohol Tissue Research Resource (MATRR)R24AA019431 · NIAAA · OREGON HEALTH & SCIENCE UNIVERSITY · PI Mary Lauren Benton, Verginia Carmella Cuzon Carlson · 2010 to 2026
$10.3M
Early Stress & Alcoholism: Neurobiological AnalysisU01AA014106 · NIAAA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI FRIEDMAN, DAVID P · 2003 to 2011
$3.4M
NIAAA NIH HHS R24 AA019431NIAAA NIH HHS U01 AA014106
6 · The paper itself

Abstract

Leucine-rich repeat kinase 2 (LRRK2) is a large protein involved in the pathogenesis of Parkinson's disease (PD). It has been demonstrated that PD is mainly conferred by LRRK2 mutations that bring about increased kinase activity. As a consequence, selective inhibition of LRRK2 may help to recover the normal functions of LRRK2, thereby serving as a promising alternative therapeutic target for PD treatment. The mapping of LRRK2 by positron emission tomography (PET) studies allows a thorough understanding of PD and other LRRK2-related disorders; it also helps to validate and translate novel LRRK2 inhibitors. However, no LRRK2 PET probes have yet been reported in the primary literature. Herein we present a facile synthesis and preliminary evaluation of [

Indexed as

AnimalsBrainCarbon RadioisotopesFemaleHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LigandsMacaca mulattaMiceMorpholinesParkinson DiseasePositron-Emission TomographyProtein Kinase InhibitorsPyrimidinesRadiopharmaceuticalsRats, Sprague-DawleyCarbon-11Carbon RadioisotopesLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LigandsMorpholinesProtein Kinase InhibitorsPyrimidinesRadiopharmaceuticalscarbon-11GNE-1023leucine-rich repeat kinase 2Parkinson's diseasepositron emission tomography

Identifiers

PMID31365783
PMCPMC6726558
OpenAlexW2966043314

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.